Oncotarget

Researchers conduct a Phase 1B clinical trial to test the efficacy of combining P10's PODRIA vaccine with chemotherapy for HR-positive/HER-2 breast cancer patients. The goal is to enhance immune responses and improve long-term survival benefits. Treatment schedules play a crucial role in generating strong antibody responses for better therapeutic outcomes.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 22. https://www.oncotarget.com/archive/v12/i22/ Research Paper (Cover) - “P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses” https://doi.org/10.18632/oncotarget.28083 Research Paper - “Dishevelled-1 DIX and PDZ domain lysine residues regulate oncogenic Wnt signaling” https://doi.org/10.18632/oncotarget.28089 Research Paper - “THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma” https://doi.org/10.18632/oncotarget.28099 Research Paper - “Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization” https://doi.org/10.18632/oncotarget.28092 Review - “Emerging approaches of wound healing in experimental models of high-grade oral mucositis induced by anticancer therapy” https://doi.org/10.18632/oncotarget.28091 Editorial - “Future directions for immunotherapy in meningioma treatment” https://doi.org/10.18632/oncotarget.27994 (PDF Download) Editorial - “Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer” https://doi.org/10.18632/oncotarget.28007 (PDF Download) Keywords - cancer vaccine, dishevelled (DVL), next-generation sequencing (NGS), oral mucositis, meningioma, immunotherapy, HER2 low, pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The podcast delves into how cancer cells resist epithelial mesenchymal transition (EMT) and explores the irreversibility of MET. Researchers uncover global epigenetic programs, the role of GRHL2, and mechanisms behind resistance in epithelial tumor cells. They also discuss spatial effects on cell populations and molecular mechanisms in EMT and MET transitions.

Exploring the molecular target of Temazolamide in cancer cells and the resistance mechanisms hindering its efficacy. Researchers investigate the potential of combining ATRI inhibition with TMZ to reverse chemo-resistance, with a focus on low Rev3L mRNA expression as a selection criterion for enhanced efficacy in tumor treatment.

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 21. https://www.oncotarget.com/archive/v12/i21/ Priority Research Paper (Cover) - “ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide” https://doi.org/10.18632/oncotarget.28090 Research Paper - “Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab” https://doi.org/10.18632/oncotarget.28086 Research Paper - “Luminescence complementation technology for the identification of MYC:TRRAP inhibitors” https://doi.org/10.18632/oncotarget.28078 Research Paper - “TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan” https://doi.org/10.18632/oncotarget.28073 Research Paper - “The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey” https://doi.org/10.18632/oncotarget.28076 Research Paper - “Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma” https://doi.org/10.18632/oncotarget.28069 Research Paper - “Trends in oligomannosylation and α1,2-mannosidase expression in human cancers” https://doi.org/10.18632/oncotarget.28064 Research Paper - “TP53 mutations determined by targeted NGS in breast cancer: a case-control study” https://doi.org/10.18632/oncotarget.28071 Research Paper - “Association of four genetic variants with colorectal cancer in Kazakhstan population” https://doi.org/10.18632/oncotarget.28070 Editorial - “Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?” https://doi.org/10.18632/oncotarget.27987 (PDF Download) Research Perspective - “Neddylation and anti-tumor immunity” https://doi.org/10.18632/oncotarget.28019 Keywords - ATR, cancer immunotherapy, drug discovery, comprehensive genomic profiling, glioblastoma, oligomannose, TP53 mutations, head and neck cancer, neddylation, breast cancer, colorectal cancer, multiple myeloma (MM), cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The podcast delves into the world of gene editing in tumors using CRISPR/Cas9 technology. Researchers explore the role of IGFBP2, a gene regulated by DNA methylation, in cancer progression. The study uncovers transcriptional changes and functional effects on cell fate in different tumor settings, shedding light on the potential of CRISPR/Cas9 epigenetic editing in stable epigenetic modifications for tumor research.

Learn about the role of mTOR protein complexes in cell growth, potential treatments for NSCLC targeting the PI3K/AKT/mTOR pathway, and a groundbreaking study on drug combinations showing high synergistic activity in adenocarcinoma NSCLC.

The podcast delves into the discovery of ubiquitin proteins and their role in initiating protein interactions, denoting them for degradation, and altering cellular activity. Researchers discuss the importance of HIF-1 alpha in tumorigenesis and the potential therapeutic implications of targeting this protein in cancer cells.

Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 20. https://www.oncotarget.com/archive/v12/i20/ Priority Research Paper (Cover) - “Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase” https://doi.org/10.18632/oncotarget.28081 Research Paper - “A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs” https://doi.org/10.18632/oncotarget.28079 Research Paper - “Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients” https://doi.org/10.18632/oncotarget.28082 Research Paper - “Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells” https://doi.org/10.18632/oncotarget.28075 Research Paper - “Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells” https://doi.org/10.18632/oncotarget.28072 Research Paper - “Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma” https://doi.org/10.18632/oncotarget.28074 Research Paper - “Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma” https://doi.org/10.18632/oncotarget.28067 Research Paper - “NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells” https://doi.org/10.18632/oncotarget.28063 Research Paper - “Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma” https://doi.org/10.18632/oncotarget.28060 Review - “Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma” https://doi.org/10.18632/oncotarget.28080 Editorial - “Fibrocytes in primary myelofibrosis” https://doi.org/10.18632/oncotarget.27971 (PDF Download) Research Perspective - “Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers” https://doi.org/10.18632/oncotarget.27983 Keywords - cytokine profiling, breast cancer, colorectal cancer, colon cancer, lung cancer, multiple myeloma (MM), cellular therapy, T-cell lymphoma, cholangiocarcinoma, basal cell carcinoma, myelofibrosis, gastrointestinal cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Nutrigenomics research shows sulforaphane from cruciferous vegetables can activate protective genes and inhibit tumor growth. Combining sulforaphane with acetazolamide has shown effective cancer cell inhibition. Researchers explored these effects on bronchial carcinoid cancer cells and discussed the potential therapeutic benefits.